# Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01845831` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01845831](<https://clinicaltrials.gov/study/NCT01845831>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01845831

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.

## Technical summary

Registry record NCT01845831. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-05-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 292 participants (enrolled count; ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Start date: 2013-08 (registry gives no type) (ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Primary completion: 2016-04 (actual) (ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Completion: 2016-04 (actual) (ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Results first posted: 2017-05-30 (ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01845831, source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01845831-2017-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Basal Bolus
- Intervention (Drug): Metformin and Sitagliptin
- Intervention (Drug): Glargine
- Intervention (Drug): Glargine 50%
- Intervention (Drug): Glargine 80%
- Lead sponsor: Emory University
- Lead sponsor class: OTHER
- Collaborator: Merck Sharp & Dohme LLC
- Collaborator class: INDUSTRY
- Collaborator: Temple University
- Collaborator class: OTHER
- Collaborator: University of Michigan
- Collaborator class: OTHER
- Collaborator: Ohio University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)
- Registry lists this organization as a collaborator: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Temple University (`cardio:org-temple-university`)
- Registry lists this organization as a collaborator: University of Michigan (`cardio:org-university-of-michigan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial (`cardio:pubmed-27964837`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f8f4a14dc5773c45e82604e504fdc386a32c8ae10087499b0fed3bb3aff4ae2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
